The growing interest in medical weight management has driven the development of innovative treatments, including Orforglipron — a promising new oral option for patients struggling with obesity or excess weight. As research continues to advance, Orforglipron may soon become an important addition to the range of weight loss therapies available in Australia.
Orforglipron (pronounced or-for-GLIP-ron) is a non-peptide oral GLP-1 receptor agonist, closely related to oral semaglutide (Rybelsus®). It is currently being studied for its role in both weight loss and type 2 diabetes management.
Unlike traditional injectable GLP-1 medications such as Ozempic® or Saxenda®, Orforglipron is taken as a once-daily tablet, providing a convenient, needle-free alternative for patients.
Moreover, the medication works by mimicking GLP-1 (glucagon-like peptide-1) — a natural hormone that regulates appetite, blood sugar, and digestion. By enhancing GLP-1 activity, Orforglipron helps reduce hunger, promote fullness, and support gradual, sustainable weight loss.
Learn more about how GLP-1 medications work from https://www.mayoclinic.org/healthy-lifestyle/consumer-health/expert-answers/infrared-sauna/faq-20057954
Early clinical trials have produced encouraging results. In phase 2 studies, patients taking Orforglipron lost an average of 9–15% of their body weight over several months, depending on dosage.
These results are comparable to, and in some cases approach, outcomes seen with injectable GLP-1 medications.
Furthermore, researchers found that participants experienced improved metabolic health markers, such as blood sugar and cholesterol levels. Although additional studies are ongoing, Orforglipron’s early success indicates that it could soon offer a powerful, non-injectable treatment option for those seeking medical weight loss.
At present, Orforglipron is not yet approved for general use in Australia. It is still progressing through clinical trials and Therapeutic Goods Administration (TGA) evaluation.
However, once approved, it is expected to become a highly sought-after oral alternative for patients who prefer tablets over injections.
Until then, Australians can access other GLP-1 medications such as Ozempic® (semaglutide), Wegovy® (semaglutide 2.4 mg), and Saxenda® (liraglutide). These medications are already available and prescribed for both weight management and type 2 diabetes. https://www.tga.gov.au/
Like other GLP-1 receptor agonists, Orforglipron may cause mild gastrointestinal side effects, particularly when treatment begins.
Common effects include:
Nausea
Diarrhoea
Constipation
Indigestion
These symptoms are usually temporary and improve as the body adjusts. On rare occasions, more serious gastrointestinal issues can occur, and therefore patients should always consult their healthcare provider before starting any new medication.
The introduction of an oral GLP-1 medication marks an exciting shift in obesity and diabetes management.
Previously, patients who were hesitant to use injections had limited access to the full benefits of GLP-1 therapy.
Orforglipron changes that by offering an effective, once-daily oral tablet that can help many people achieve meaningful weight reduction without the need for injections.
In addition, oral therapy may improve treatment adherence, since taking a tablet is simpler and more comfortable for most patients. Consequently, this can lead to better long-term outcomes in both weight and metabolic control.
At Holistica Health, our medical team monitors emerging therapies like Orforglipron to ensure that our patients receive safe, evidence-based care.
We already offer a comprehensive range of GLP-1 treatments, including Mounjaro®, Wegovy®, Ozempic®, and Saxenda®, delivered through our Telehealth Weight Loss Clinic.
Our doctors create personalised treatment plans that combine medical therapy, nutrition, lifestyle adjustments, and regular follow-ups. As new therapies like Orforglipron become available, they will be carefully integrated into our holistic, patient-centred approach to weight management. https://holisticahealth.com.au/services/gp-telehealth-service/
Orforglipron represents a significant advancement in medical weight loss. It combines the proven benefits of GLP-1 therapy with the convenience of an oral tablet, offering a practical, effective alternative for patients who prefer a needle-free option.
Although not yet available in Australia, the future looks bright for this innovative medication.